Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00809068
Registration number
NCT00809068
Ethics application status
Date submitted
10/06/2008
Date registered
16/12/2008
Date last updated
2/02/2010
Titles & IDs
Public title
High-density Lipoprotein (HDL) Cholesterol in Women Taking Tibolone
Query!
Scientific title
Effects of Tibolone and PPARa-agonist on HDL Metabolism in Postmenopausal Women
Query!
Secondary ID [1]
0
0
SCGH Research Grant
Query!
Secondary ID [2]
0
0
ID: 2005-001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
TibFen
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
HDL Cholesterol
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - fenofibrate and tibolone
Treatment: Drugs - tibolone
Active comparator: 1 - fenofibrate and tibolone
Sham comparator: 2 - tibolone
Treatment: Drugs: fenofibrate and tibolone
fenofibrate 160mg daily 8 weeks tibolone 2.5mg daily 23 weeks
Treatment: Drugs: tibolone
tibolone 2.5 mg daily 23 weeks
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
HDL subpopulation analysis
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
August 2009
Query!
Secondary outcome [1]
0
0
Increase in HDL subpopulations
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
December 2009
Query!
Eligibility
Key inclusion criteria
* Post-menopausal women
* More than 6 months of amenorrhoea
* Raised FSH and low oestradiol level
* If hysterectomised, raised FSH and low oestradiol level
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
70
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
* Diabetes
* Renal failure
* Proteinuria
* High alcohol intake
* Regular endurance exercise
* Active weight loss of dieting
* Smokers
* Agents known to influence lipid metabolism
* Major systemic illness
* Intolerance to tibolone and fenofibrate
* Cholelithiasis
* CK and ALT > 2ULN
* Bleeding disorders
* Peptic ulcer disease.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/08/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/10/2009
Query!
Sample size
Target
20
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
WA
Query!
Recruitment hospital [1]
0
0
Keogh Institute for Medical Research, 'A' Block 3rd Floor, QE II Medical Centre, Nedlands - Perth
Query!
Recruitment postcode(s) [1]
0
0
6009 - Perth
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Keogh Institute for Medical Research
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Tibolone (Livial) has been shown in previous studies to lower HDL cholesterol by up to 40%. This study aims to study the effects of fenofibrate on HDL and subfractions in women taking tibolone.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00809068
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bronwyn G Stuckey, MBBS FRACP
Query!
Address
0
0
Keogh Institute for Medical Research
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT00809068
Download to PDF